Gossamer Bio Stock Net Asset
| GOSS Stock | USD 0.70 0.04 6.06% |
Gossamer Bio fundamentals help investors to digest information that contributes to Gossamer Bio's financial success or failures. It also enables traders to predict the movement of Gossamer Stock. The fundamental analysis module provides a way to measure Gossamer Bio's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Gossamer Bio stock.
Gossamer | Net Asset |
Gossamer Bio Company Net Asset Analysis
Gossamer Bio's Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Current Gossamer Bio Net Asset | 311.92 M |
Most of Gossamer Bio's fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Gossamer Bio is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Gossamer Net Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for Gossamer Bio is extremely important. It helps to project a fair market value of Gossamer Stock properly, considering its historical fundamentals such as Net Asset. Since Gossamer Bio's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Gossamer Bio's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Gossamer Bio's interrelated accounts and indicators.
Click cells to compare fundamentals
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
| Competition |
Gossamer Total Assets
Total Assets |
|
Based on the recorded statements, Gossamer Bio has a Net Asset of 311.92 M. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The net asset for all United States stocks is notably lower than that of the firm.
Gossamer Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Gossamer Bio's direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Gossamer Bio could also be used in its relative valuation, which is a method of valuing Gossamer Bio by comparing valuation metrics of similar companies.Gossamer Bio is currently under evaluation in net asset category among its peers.
Gossamer Bio Current Valuation Drivers
We derive many important indicators used in calculating different scores of Gossamer Bio from analyzing Gossamer Bio's financial statements. These drivers represent accounts that assess Gossamer Bio's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Gossamer Bio's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 855.6M | 662.5M | 846.5M | 183.5M | 139.3M | 132.3M | |
| Enterprise Value | 760.0M | 360.2M | 848.3M | 297.3M | 319.6M | 613.3M |
Gossamer Bio Institutional Holders
Institutional Holdings refers to the ownership stake in Gossamer Bio that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Gossamer Bio's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Gossamer Bio's value.| Shares | Silverarc Capital Management, Llc | 2024-06-30 | 5.5 M | T. Rowe Price Associates, Inc. | 2024-06-30 | 5.5 M | Eversept Partners, Llc | 2024-09-30 | 5 M | Hillhouse Capital Advisors, Ltd. | 2024-09-30 | 5 M | Monaco Asset Management | 2024-09-30 | 3.9 M | Deutsche Bank Ag | 2024-06-30 | 3.8 M | Opaleye Management Inc | 2024-09-30 | 3.7 M | Junked Platinum Investment Management Ltd | 2024-09-30 | 3.5 M | Ci Private Wealth Llc | 2024-06-30 | 3.4 M | Nea Management Company, Llc | 2024-06-30 | 18.1 M | Artal Group S A | 2024-06-30 | 13.3 M |
Gossamer Fundamentals
| Return On Equity | -0.9 | ||||
| Return On Asset | -0.11 | ||||
| Profit Margin | (0.68) % | ||||
| Operating Margin | (3.58) % | ||||
| Current Valuation | 35.6 M | ||||
| Shares Outstanding | 226.6 M | ||||
| Shares Owned By Insiders | 3.32 % | ||||
| Shares Owned By Institutions | 77.46 % | ||||
| Number Of Shares Shorted | 6.53 M | ||||
| Price To Earning | (4.61) X | ||||
| Price To Book | 2.94 X | ||||
| Price To Sales | 1.51 X | ||||
| EBITDA | (172.15 M) | ||||
| Net Income | (179.82 M) | ||||
| Cash And Equivalents | 304.38 M | ||||
| Cash Per Share | 3.29 X | ||||
| Total Debt | 212.46 M | ||||
| Debt To Equity | 3.86 % | ||||
| Current Ratio | 5.93 X | ||||
| Book Value Per Share | 0.24 X | ||||
| Cash Flow From Operations | (159.16 M) | ||||
| Short Ratio | 7.99 X | ||||
| Earnings Per Share | (0.25) X | ||||
| Price To Earnings To Growth | (0.63) X | ||||
| Target Price | 6.72 | ||||
| Number Of Employees | 135 | ||||
| Beta | 1.96 | ||||
| Market Capitalization | 159.01 M | ||||
| Total Asset | 311.92 M | ||||
| Retained Earnings | (1.21 B) | ||||
| Working Capital | 254.92 M | ||||
| Current Asset | 441.63 M | ||||
| Current Liabilities | 39.84 M | ||||
| Net Asset | 311.92 M |
About Gossamer Bio Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Gossamer Bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Gossamer Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Gossamer Bio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Gossamer Stock Analysis
When running Gossamer Bio's price analysis, check to measure Gossamer Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gossamer Bio is operating at the current time. Most of Gossamer Bio's value examination focuses on studying past and present price action to predict the probability of Gossamer Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gossamer Bio's price. Additionally, you may evaluate how the addition of Gossamer Bio to your portfolios can decrease your overall portfolio volatility.